BR9507467A - Processos para produzir um inibidor de serina-protease recombinante modular uma serina-protease diagnosticar pacientes suspeitos de apresentarem uma mutação em um gene codificador de um inibidor de serina-protease tratar uma condição associada ás serina-proteases em um paciente e inibir os mecanismos moleculares e celulares da inflamação e reduzir os danos nos tecidos em uma célula ou tecido composição capaz de modular efetivamente a atividade de serina-protease uso da composição análogo de a-1- antiquimotripsina do tipo selvagen humana sequência de ácidos nucléicos vetor de expressão célula hospedeira e preparação de protina - Google Patents

Processos para produzir um inibidor de serina-protease recombinante modular uma serina-protease diagnosticar pacientes suspeitos de apresentarem uma mutação em um gene codificador de um inibidor de serina-protease tratar uma condição associada ás serina-proteases em um paciente e inibir os mecanismos moleculares e celulares da inflamação e reduzir os danos nos tecidos em uma célula ou tecido composição capaz de modular efetivamente a atividade de serina-protease uso da composição análogo de a-1- antiquimotripsina do tipo selvagen humana sequência de ácidos nucléicos vetor de expressão célula hospedeira e preparação de protina

Info

Publication number
BR9507467A
BR9507467A BR9507467A BR9507467A BR9507467A BR 9507467 A BR9507467 A BR 9507467A BR 9507467 A BR9507467 A BR 9507467A BR 9507467 A BR9507467 A BR 9507467A BR 9507467 A BR9507467 A BR 9507467A
Authority
BR
Brazil
Prior art keywords
serine
serine protease
modulating
protease inhibitor
protin
Prior art date
Application number
BR9507467A
Other languages
English (en)
Inventor
Harvey Rubin
Barry S Cooperman
Norman Schechter
Michael Plotnick
Zhi Mei Wang
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BR9507467A publication Critical patent/BR9507467A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9507467A 1994-04-18 1995-04-11 Processos para produzir um inibidor de serina-protease recombinante modular uma serina-protease diagnosticar pacientes suspeitos de apresentarem uma mutação em um gene codificador de um inibidor de serina-protease tratar uma condição associada ás serina-proteases em um paciente e inibir os mecanismos moleculares e celulares da inflamação e reduzir os danos nos tecidos em uma célula ou tecido composição capaz de modular efetivamente a atividade de serina-protease uso da composição análogo de a-1- antiquimotripsina do tipo selvagen humana sequência de ácidos nucléicos vetor de expressão célula hospedeira e preparação de protina BR9507467A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22928694A 1994-04-18 1994-04-18
US08/276,936 US5612194A (en) 1989-06-23 1994-07-19 Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
PCT/US1995/004488 WO1995028422A1 (en) 1994-04-18 1995-04-11 Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors

Publications (1)

Publication Number Publication Date
BR9507467A true BR9507467A (pt) 1997-09-23

Family

ID=26923159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507467A BR9507467A (pt) 1994-04-18 1995-04-11 Processos para produzir um inibidor de serina-protease recombinante modular uma serina-protease diagnosticar pacientes suspeitos de apresentarem uma mutação em um gene codificador de um inibidor de serina-protease tratar uma condição associada ás serina-proteases em um paciente e inibir os mecanismos moleculares e celulares da inflamação e reduzir os danos nos tecidos em uma célula ou tecido composição capaz de modular efetivamente a atividade de serina-protease uso da composição análogo de a-1- antiquimotripsina do tipo selvagen humana sequência de ácidos nucléicos vetor de expressão célula hospedeira e preparação de protina

Country Status (19)

Country Link
US (1) US5612194A (pt)
EP (1) EP0765342A1 (pt)
JP (1) JPH10501404A (pt)
CN (1) CN1146207A (pt)
AP (1) AP9600905A0 (pt)
AU (1) AU2382195A (pt)
BG (1) BG100981A (pt)
BR (1) BR9507467A (pt)
CA (1) CA2188180A1 (pt)
CZ (1) CZ300396A3 (pt)
FI (1) FI964174A (pt)
HU (1) HUT75358A (pt)
LV (1) LV11801A (pt)
NO (1) NO964416D0 (pt)
OA (1) OA10727A (pt)
PL (1) PL316949A1 (pt)
SI (1) SI9520043A (pt)
SK (1) SK130696A3 (pt)
WO (1) WO1995028422A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827662A (en) * 1989-06-23 1998-10-27 The Trustees Of The University Of Pennsylvania Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
US7171016B1 (en) 1993-11-18 2007-01-30 Digimarc Corporation Method for monitoring internet dissemination of image, video and/or audio files
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
AU3866799A (en) * 1998-05-04 1999-11-23 Zymogenetics Inc. Cytoplasmic antiproteinase-3 coding sequence in gene therapy
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU2002241664A1 (en) * 2000-12-29 2002-07-16 Kimberly-Clark Worldwide, Inc. Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover
CA2521410C (en) * 2003-04-04 2014-06-03 Universite De Lausanne Inhibitor proteins of a protease and use thereof
USPP15990P3 (en) * 2003-04-23 2005-09-20 J. C. Bakker & Sons Limited Lilac plant named ‘Golden Eclipse’
CA2536918A1 (en) * 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
US20080115232A1 (en) * 2004-09-29 2008-05-15 Hiroshi Onozato Amphidiploid Aquatic Animal and Method of Breeding the Same
US20070104699A1 (en) * 2005-09-29 2007-05-10 University Of Alberta Compositions for and methods of granzyme B inhibition
CA2839917A1 (en) 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
JP2015111050A (ja) * 2012-03-28 2015-06-18 国立大学法人九州大学 Ｋａｌｌｉｓｔａｔｉｎ蛋白質による脳梗塞検査方法
CN103243105B (zh) * 2013-05-19 2018-11-02 中国农业科学院兰州兽医研究所 一种旋毛虫重组蛋白及应用
CN103275214A (zh) * 2013-06-08 2013-09-04 天津师范大学 对虾丝氨酸蛋白酶抑制剂的基因工程制备与鉴定方法
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
CN104628845B (zh) * 2015-01-21 2017-12-08 中国人民解放军第二军医大学 一种发形霞水母丝氨酸蛋白酶抑制剂及其编码基因与应用
CN106478812B (zh) * 2016-10-21 2020-11-20 沈阳药科大学 丝氨酸蛋白酶抑制剂-3及其功能、制备方法和应用
CN110068676A (zh) * 2019-03-22 2019-07-30 同济大学 分泌蛋白Serpin A3在预测心肌损伤诊断试剂中的应用
CN110330564B (zh) * 2019-08-06 2022-09-20 上海景晗生物科技有限公司 丝氨酸蛋白酶抑制剂及其最小功能片段和免疫抑制作用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252725A (en) * 1989-06-23 1993-10-12 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production

Also Published As

Publication number Publication date
WO1995028422A1 (en) 1995-10-26
CA2188180A1 (en) 1995-10-26
FI964174A0 (fi) 1996-10-17
AU2382195A (en) 1995-11-10
EP0765342A1 (en) 1997-04-02
US5612194A (en) 1997-03-18
BG100981A (en) 1998-01-30
FI964174A (fi) 1996-10-17
HU9602886D0 (en) 1996-12-30
CN1146207A (zh) 1997-03-26
HUT75358A (en) 1997-05-28
NO964416L (no) 1996-10-17
LV11801A (lv) 1997-06-20
CZ300396A3 (en) 1997-08-13
PL316949A1 (en) 1997-02-17
JPH10501404A (ja) 1998-02-10
OA10727A (en) 2002-12-09
SK130696A3 (en) 1997-07-09
SI9520043A (en) 1997-08-31
AP9600905A0 (en) 1997-01-31
NO964416D0 (no) 1996-10-17

Similar Documents

Publication Publication Date Title
BR9507467A (pt) Processos para produzir um inibidor de serina-protease recombinante modular uma serina-protease diagnosticar pacientes suspeitos de apresentarem uma mutação em um gene codificador de um inibidor de serina-protease tratar uma condição associada ás serina-proteases em um paciente e inibir os mecanismos moleculares e celulares da inflamação e reduzir os danos nos tecidos em uma célula ou tecido composição capaz de modular efetivamente a atividade de serina-protease uso da composição análogo de a-1- antiquimotripsina do tipo selvagen humana sequência de ácidos nucléicos vetor de expressão célula hospedeira e preparação de protina
KR100699084B1 (ko) 어류 세린 프로티나제,그 약제학적 및 화장품으로서의 용도
US4645668A (en) Method for the prevention and treatment of scars with enzymes
Fosang et al. Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins
Melchiori et al. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment
ES2553184T3 (es) Colagenasa para tratar la celulitis
EP2205623B1 (en) Protective skin care tetrapeptides
ES2194720T3 (es) Enzimas para el tratamiento de diabetes mellitus tipo i.
BR9713108A (pt) Colagenase recombinante do tipo i de clostridium histolytucum e o uso da mesma para o isolamento de células e de grupos de células
KR20040081158A (ko) 성장 인자 및 프로테아제 효소의 배합물
US11491214B2 (en) Treatment of abnormal cutaneous scarring
BR9710615A (pt) Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea.
Liu et al. The regulatory effects of cytokines on lymphatic angiogenesis
US20110117208A1 (en) Chronic wound treatment
KR0167344B1 (ko) 프로테아제 억제제
US20050048046A1 (en) Use of placental alkaline phosphatase to promote skin cell proliferation
Dumas et al. Collagenase in mineralized tissues of human teeth
WALREAVENS et al. Isolation and preliminary characterization of the cysteine-proteinases from the latex of Carica candamarcensis Hook
Ghahary et al. Interferons gamma and alpha‐2b differentially regulate the expression of collagenase and tissue inhibitor of metalloproteinase‐1 messenger RNA in human hypertrophic and normal dermal fibroblasts
Gadher et al. Degradation of cartilage collagens type II, IX, X and XI by enzymes derived from human articular chondrocytes
RU2639573C2 (ru) Бифункциональный пептид
DK274990A (da) Vaevsplasminogenaktivator-(t-pa)-varianter, dma-sekvenser, som koder for disse, replicerbare udtrykkelsesvektorer for dna-sekvenserne, eukaryote vaertsceller transformeret med vektorerne og farmaceutiske praeparater indeholdende t-pa-varianterne
Glyantsev et al. Crab collagenase in wound debridement
Mekkes et al. In vitro tissue-digesting properties of krill enzymes compared with fibrinolysin/DNAse, papain and placebo
ES2072280T3 (es) Enzimas catabolicas para la induccion del factor de necrosis tumoral (tnf).

Legal Events

Date Code Title Description
FD5 Application fees: dismissal - article 86 of industrial property law